Skip to main content

and
  1. Article

    Open Access

    Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation

    In a 3-arm presurgical trial, four-six weeks exemestane 25 mg three times/week (TIW) was non-inferior to 25 mg/day (QD) in suppressing circulating estradiol in postmenopausal women with ER-positive breast canc...

    Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini in npj Breast Cancer (2024)

  2. Article

    Open Access

    Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

    Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 ...

    Andrea DeCensi, Harriet Johansson, Thomas Helland, Matteo Puntoni in npj Breast Cancer (2021)